Related Experiment Video
Updated: May 26, 2026
10:23
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
Published on: April 17, 2017
Pharmacogenetics of hepatitis C
Vincent Soriano1, Eva Poveda, Eugenia Vispo
1Infectious Diseases Department, Hospital Carlos III, Madrid, Spain. vsoriano@dragonet.es
The Journal of Antimicrobial Chemotherapy
|December 24, 2011
Summary
Host genetics significantly impact hepatitis C virus (HCV) infection outcomes, influencing treatment response and toxicity. Genetic markers like IL28B SNPs remain valuable for guiding therapy, especially in coinfected patients.
Area of Science:
- Virology
- Genetics
- Immunology
Background:
- Host genomics play a crucial role in determining outcomes of hepatitis C virus (HCV) infections.
- Understanding these genetic influences has reshaped perspectives on HCV pathogenesis and treatment strategies.
Purpose of the Study:
- To explore the impact of host genetic variations, specifically single-nucleotide polymorphisms (SNPs) in IL28B, ITPA, and LDLR genes, on HCV infection.
- To assess the potential of these genetic markers in refining pharmacogenomic predictions for antiviral response and toxicity.
- To identify new therapeutic targets for hepatitis C based on host genetic factors.
Main Methods:
- Review of recent discoveries and literature on host genomics and HCV infection.
- Analysis of the significance of specific gene polymorphisms (IL28B, ITPA, LDLR) in relation to HCV outcomes.
- Evaluation of the role of genetic markers in the era of direct-acting antivirals (DAAs) and traditional therapies.
Main Results:
- Single-nucleotide polymorphisms (SNPs) in IL28B, ITPA, and LDLR genes influence HCV infection outcomes.
- These genetic markers can aid in predicting antiviral response and drug-related toxicities.
- Host genetics may still inform treatment duration decisions, even with potent DAAs.
Conclusions:
- Host genetic factors are pivotal in understanding and managing hepatitis C virus (HCV) infection.
- Pharmacogenomic predictions and the discovery of novel therapeutic targets can be advanced by recognizing genetic influences.
- Genetic markers retain predictive value for treatment outcomes, particularly in specific populations like HIV/HCV-coinfected patients receiving peginterferon-α/ribavirin therapy.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...